Sumitomo Mitsui Trust Group Inc. Increases Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 293,542 shares of the biopharmaceutical company’s stock after purchasing an additional 2,066 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.23% of Alnylam Pharmaceuticals worth $95,721,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the business. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $243,000. GAMMA Investing LLC boosted its holdings in Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock valued at $166,000 after acquiring an additional 77 shares during the period. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in shares of Alnylam Pharmaceuticals by 3.5% during the first quarter. Robeco Institutional Asset Management B.V. now owns 103,481 shares of the biopharmaceutical company’s stock valued at $27,942,000 after purchasing an additional 3,487 shares during the period. Finally, Sequoia Financial Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 3.0% in the first quarter. Sequoia Financial Advisors LLC now owns 3,395 shares of the biopharmaceutical company’s stock worth $917,000 after purchasing an additional 99 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several analyst reports. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Needham & Company LLC raised their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Raymond James Financial initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price target on the stock. Citigroup increased their price objective on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Finally, Piper Sandler boosted their target price on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $466.92.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 8,924 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the sale, the chief executive officer owned 65,409 shares in the company, valued at $29,568,138.45. This represents a 12.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05. Following the transaction, the executive vice president owned 25,231 shares of the company’s stock, valued at $11,405,673.55. The trade was a 8.82% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,144 shares of company stock valued at $44,160,261. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $463.43 on Friday. The business’s fifty day moving average is $459.27 and its 200 day moving average is $360.97. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock has a market cap of $60.75 billion, a price-to-earnings ratio of -187.62 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.